Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Stopped early · Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
Key facts
- Study ID
- NCT00068770
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 35
- Starts
- 2003-10-01
- Expected to finish
- 2006-05-01
- Last updated by the study team
- 2015-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
- Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
- Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
- Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.